Novartis Signs $1.4B Molecular Glue Deal with Orionis
Novartis Signs $1.4B Molecular Glue Deal with Orionis.
Orionis Biosciences
Private
Orionis Biosciences is a life sciences company pioneering conditionally active immunotherapies (A-Kines) and molecular glue drug discovery (AlloGlues) for cancer and immunology. The company has research collaborations with Novartis and Genentech/Roche, and is advancing internal programs in oncology and immunology.
Company Info
Sector:Biotechnology / Induced Proximity Therapeutics
Headquarters:Waltham, Massachusetts, USA (Research facility in Ghent, Belgium)
Founded:2015
Website:www.orionisbio.com/
Funding Round:Series C and ongoing partnerships
Total Funding:~$200M (cumulative equity + upfront payments)
Funding & Investor Relations
Notable Investors
- Novartis (collaboration partner)
- Genentech / Roche (collaboration partner)
- Atlas Venture
- LSP (Life Sciences Partners)
- Bristol-Myers Squibb
- INKEF Capital
- VIB (Flemish Institute for Biotechnology)
IPO Outlook / Plans
None publicly disclosed; private biotech with strong pharma partnership revenue.
Upcoming Milestones & Key Dates
2026
Milestone
Nomination of first development candidate from Novartis collaboration
2026 / 2027
Clinical Trial
Phase 1 clinical updates for ORB-011 and ORB-021 A-Kine programs
Clinical Development Pipeline
ORB-011
Target: Conditionally active cDC1-targeted interferon (A-Kine)ORB-021
Target: Conditionally active targeted cytokine (A-Kine)AlloGlue programs (with Novartis)
Target: Multiple molecular glue degraders via induced proximityAlloGlue programs (with Genentech/Roche)
Target: Multiple molecular glue degraders via induced proximityRecent News
Novartis Signs $1.4B Molecular Glue Deal with Orionis
Novartis Signs $1.4B Molecular Glue Deal with Orionis.
Leadership Team
Careers & Job Openings